Sumitomo Mitsui Trust Holdings, Inc. Neurocrine Biosciences Inc Transaction History

Sumitomo Mitsui Trust Holdings, Inc.

$138 Billion
Q1 2025

A detailed history of Sumitomo Mitsui Trust Holdings, Inc. transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Sumitomo Mitsui Trust Holdings, Inc. holds 231,458 shares of NBIX stock, worth $28.9 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

231,458

Previous 232,857 0.6%

Holding current value

$28.9 Million

Previous $31.8 Million 19.46%

% of portfolio

0.02%

Previous 0.02%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 Apr 25, 2025	SELL	$107.22 - $153.29 $150,000 - $214,452	-1,399 Reduced 0.6%	231,458 $25.6 Million
Q4 2024 Jan 28, 2025	BUY	$111.62 - $139.44 $102,243 - $127,727	916 Added 0.39%	232,857 $31.8 Million
Q3 2024 Nov 05, 2024	SELL	$114.58 - $153.15 $1.32 Million - $1.76 Million	-11,502 Reduced 4.72%	231,941 $26.7 Million
Q2 2024 Jul 19, 2024	SELL	$130.86 - $143.19 $1.19 Million - $1.31 Million	-9,122 Reduced 3.61%	243,443 $33.5 Million
Q1 2024 Apr 19, 2024	BUY	$130.4 - $143.74 $1.13 Million - $1.24 Million	8,630 Added 3.54%	252,565 $34.8 Million
Q4 2023 Jan 30, 2024	BUY	$106.07 - $132.76 $1.31 Million - $1.64 Million	12,382 Added 5.35%	243,935 $32.1 Million
Q3 2023 Oct 30, 2023	SELL	$94.02 - $117.1 $1.03 Million - $1.28 Million	-10,951 Reduced 4.52%	231,553 $26 Million
Q2 2023 Jul 31, 2023	SELL	$89.53 - $104.87 $3.8 Million - $4.45 Million	-42,423 Reduced 14.89%	242,504 $22.9 Million
Q1 2023 Apr 27, 2023	BUY	$94.11 - $123.02 $82,534 - $107,888	877 Added 0.31%	284,927 $28.8 Million
Q4 2022 Jan 30, 2023	SELL	$106.72 - $127.06 $19,102 - $22,743	-179 Reduced 0.06%	284,050 $33.9 Million
Q3 2022 Oct 21, 2022	BUY	$92.03 - $107.81 $109,423 - $128,186	1,189 Added 0.42%	284,229 $30.2 Million
Q2 2022 Jul 26, 2022	BUY	$75.79 - $100.07 $236,616 - $312,418	3,122 Added 1.12%	283,040 $27.6 Million
Q1 2022 Apr 27, 2022	SELL	$72.45 - $94.81 $1.1 Million - $1.43 Million	-15,126 Reduced 5.13%	279,918 $26.2 Million
Q4 2021 Feb 02, 2022	BUY	$79.65 - $106.22 $2.44 Million - $3.25 Million	30,585 Added 11.57%	295,044 $25.1 Million
Q3 2021 Oct 25, 2021	SELL	$86.18 - $99.03 $493,552 - $567,144	-5,727 Reduced 2.12%	264,459 $25.4 Million
Q2 2021 Aug 02, 2021	SELL	$89.43 - $102.27 $3.14 Million - $3.59 Million	-35,100 Reduced 11.5%	270,186 $26.3 Million
Q1 2021 Apr 30, 2021	SELL	$87.57 - $119.4 $105,784 - $144,235	-1,208 Reduced 0.39%	305,286 $29.7 Million
Q4 2020 Feb 05, 2021	SELL	$86.91 - $108.33 $2.8 Million - $3.49 Million	-32,227 Reduced 9.51%	306,494 $29.4 Million
Q3 2020 Oct 30, 2020	SELL	$96.16 - $135.15 $8.38 Million - $11.8 Million	-87,124 Reduced 20.46%	338,721 $32.6 Million
Q2 2020 Jul 27, 2020	SELL	$85.09 - $130.36 $10.9 Million - $16.7 Million	-127,819 Reduced 23.09%	425,845 $52 Million
Q1 2020 Apr 27, 2020	BUY	$75.11 - $113.76 $19.2 Million - $29.1 Million	256,002 Added 86.0%	553,664 $47.9 Million
Q4 2019 Jan 31, 2020	BUY	$86.8 - $118.57 $25.8 Million - $35.3 Million	297,662 New	297,662 $32 Million

Others Institutions Holding NBIX

# of Institutions

649

Shares Held

97.1M

Call Options Held

749K

Put Options Held

553K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $11.9B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Sumitomo Mitsui Trust Holdings, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Sumitomo Mitsui Trust Holdings, Inc. with notifications on news.

Account

Sumitomo Mitsui Trust Holdings, Inc. Neurocrine Biosciences Inc Transaction History